- Home
- STXS
STXS
Stereotaxis Inc.
as 07-26-2024 4:00pm EST
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | ST.LOUIS |
| Market Cap: | 153.7M | IPO Year: | 2004 |
| Target Price: | $4.50 | AVG Volume (30 days): | 530.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.33 - $3.29 | Next Earning Date: | 08-12-2024 |
| Revenue: | $27,103,000 | Revenue Growth: | -2.01% |
| Revenue Growth (this year): | 15.83% | Revenue Growth (next year): | 43.34% |
Stock Insider Trading Activity of Stereotaxis Inc. (STXS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Isaac Paul J | STXS | Director | May 28 '24 | Buy | $1.96 | 1,000 | $1,957.50 | 2,758,719 | SEC Form 4 |
| Isaac Paul J | STXS | Director | May 28 '24 | Buy | $1.86 | 7,000 | $13,017.20 | 2,765,719 | SEC Form 4 |
| Isaac Paul J | STXS | Director | May 28 '24 | Buy | $1.91 | 6,000 | $11,438.40 | 2,745,693 | SEC Form 4 |
| Isaac Paul J | STXS | Director | May 28 '24 | Buy | $1.90 | 3,026 | $5,747.28 | 2,748,719 | SEC Form 4 |
| Isaac Paul J | STXS | Director | Dec 15 '23 | Buy | $1.72 | 11,060 | $19,023.20 | 2,739,693 | SEC Form 4 |
| Isaac Paul J | STXS | Director | Nov 30 '23 | Buy | $1.56 | 2,808 | $4,380.48 | 2,728,633 | SEC Form 4 |
| Isaac Paul J | STXS | Director | Nov 15 '23 | Buy | $1.44 | 20,000 | $28,800.00 | 2,692,807 | SEC Form 4 |
| Isaac Paul J | STXS | Director | Nov 15 '23 | Buy | $1.51 | 15,000 | $22,650.00 | 2,707,807 | SEC Form 4 |
| Isaac Paul J | STXS | Director | Nov 13 '23 | Buy | $1.44 | 10,000 | $14,400.00 | 2,662,807 | SEC Form 4 |
| Isaac Paul J | STXS | Director | Nov 13 '23 | Buy | $1.45 | 10,000 | $14,500.00 | 2,672,807 | SEC Form 4 |
Latest Stereotaxis Inc. News
STXS Breaking Stock News: Dive into STXS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024
GlobeNewswire
8 days ago
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
MT Newswires
2 months ago
Stereotaxis' Robotic Navigation System Used to Treat First Patients
GlobeNewswire
2 months ago
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment
Zacks
2 months ago
Stereotaxis (STXS) Gets CE Recertification for Approved Products
Zacks
2 months ago
Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias
MT Newswires
2 months ago
Stereotaxis Receives CE Mark Recertification in EU
GlobeNewswire
2 months ago
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework
Compare STXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STXS Stereotaxis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.